Inclusion Criteria:  Participant must be ≥18 years of age, able to understand the study procedures, and agrees to participate in the study by providing written informed consent Participant has histologically- or pathologically-confirmed cancer with a known sensitizing EGFR mutation. Participants must have started EGFR-TKI treatment, and subsequently had an acneiform eruption rated moderate or severe per the Leeds scale. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. Participant has a life expectancy of at least 3 months. Premenopausal participants must use highly effective method of contraception. Female participants are neither pregnant nor breastfeeding  Exclusion Criteria:  Absolute contraindications: pregnancy, breastfeeding, drug allergy  Relative contraindications:  moderate to severe hypercholesterolemia (total cholesterol >7.8 mmol/L) hypertriglyceridemia (TG >2.55 mmol/L) significant hepatic dysfunction (AST > 55IU/L, ALT > 94 IU/L) suicidal ideation, pseudotumor cerebri refractory nausea or vomiting GI pathology that would prevent absorption of oral therapy.